Cited by 265Congenital heart defects researchDevelopmental Biology and Gene RegulationCardiac electrophysiology and arrhythmias

Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa

Open access
Akiyama, Haruhiko, Chaboissier, Marie-Christine, Behringer, Richard R., Rowitch, David H., Schedl, Andreas, Epstein, Jonathan A., de Crombrugghe, Benoit·2004·Proceedings of the National Academy of Sciences

Abstract

Epithelial–mesenchymal transformation is a critical developmental process reiterated in multiple organs throughout embryogenesis. Formation of endocardial cushions, primordia of valves and septa, is a classic example of epithelial–mesenchymal transformation. Several gene mutations are known to affect cardiac valve formation. Sox9 is activated when endocardial endothelial cells undergo mesenchymal transformation and migrate into an extracellular matrix, called cardiac jelly, to form endocardial cushions. In Sox9 -null mutants, endocardial cushions are markedly hypoplastic. In these mutants, Nfatc1 is ectopically expressed and no longer restricted to endothelial cells. Further, Sox9-deficient endocardial mesenchymal cells fail to express ErbB3 , which is required for endocardial cushion cell differentiation and proliferation. Our results reveal a succession of molecular steps in the pathway of endocardial cushion development. We propose that loss of Sox9 inhibits epithelial–mesenchymal transformation after delamination and initial migration, but before definitive mesenchymal transformation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0401711101

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sox9fl/fl;Tie2-cre embryos die around E12.5 with AV developmental defects characterized by severe cushion hypoplasia.

    “These embryos die around E12.5 with AV developmental defects, characterized by severe cushion hypoplasia17.”

    From Cell diversity and plasticity during atrioventricular heart valve EMTs (2023) · cites this paper as [17]

    The Results report severely underdeveloped AV endocardial cushions in Sox9-null embryos, but say those embryos died between 11.5 and 12.0 dpc, rather than around E12.5. The Materials and Methods describe Zp3-Cre, Prm1-Cre, and Wnt1-Cre crosses, not Sox9fl/fl;Tie2-Cre embryos. The cited paper therefore supports the cushion defect in a different mutant, not the full genotype-specific claim. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • SOX9 is crucial for EMT and EndMT.

    “SOX9 is also crucial for processes involving epithelial-to-mesenchymal transition (EMT) and the closely related process endothelial-to-mesenchymal transition (EndMT) (10–12).”

    From SOX9 reprograms endothelial cells by altering the chromatin landscape (2022) · cites this paper as [11]

    The paper states that Sox9 has an essential role in EMT in the heart, specifically in endocardial endothelial cells forming cardiac cushions (opening section; Discussion). This supports its importance in cardiac EndMT, but the paper only suggests analogous roles in other organs; it does not establish that SOX9 is crucial for EMT more generally. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • In mouse, SOX9 is essential for the EndMT process that produces functioning heart valves.

    “Previous work in mouse has shown that SOX9 is essential for the EndMT process that produces functioning heart valves, as well as in skin wound healing, and acts as a master TF (11,16,17,66).”

    From SOX9 reprograms endothelial cells by altering the chromatin landscape (2022) · cites this paper as [11]

    The paper’s introductory passage states that Sox9 has an essential role in cardiac EMT, and describes endocardial cushions as the primordia of valves and septa. The Results report hypoplastic cushions in Sox9-null mouse embryos. The copy does not establish that this process produces functioning valves or assess valve function. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • EndMT is controlled by transcription factors including SNAI2, GATA4, and SOX9, activated in response to cues including TGFβ, WNT, and NOTCH.

    “This transdifferentiation event is controlled by various transcription factors, like SNAI214, GATA415, and SOX916,17, which are activated in response to cues from neighbouring cell types, including the TGFβ superfamily9,10, WNT18, and NOTCH19,20.”
  • SOX9 is critical for AV valve development, including EndMT and matrix remodelling.

    “SOX9 is critical for AV valve development, including in EndMT and matrix remodelling16,17,51,52”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 11

  1. [7]Bi, W., Huang, W., Whitworth, D. J., Deng, J. M., Zhang, Z., Behringer, R. R. & de Crombrugghe, B. (2001) Proc. Natl. Acad. Sci. USA 98, 6698-6703.
  2. [12]O'Gorman, S., Dagenais, N. A., Qian, M. & Marchuk, Y. (1997) Proc. Natl. Acad. Sci. USA 94, 14602-14607.
  3. [18]Jiang, X., Rowitch, D. H., Soriano, P., McMahon, A. P. & Sucov, H. M. (2000) Development (Cambridge, U.K.) 127, 1607-1616.
  4. [19]Epstein, J. A., Li, J., Lang, D., Chen, F., Brown, C. B., Jin, F., Lu, M. M., Thomas, M., Liu, E., Wessels, A. & Lo, C. W. (2000) Development (Cambridge, U.K.) 127, 1869-1878.
  5. [24]Lakkis, M. M. & Epstein, J. A. (1998) Development (Cambridge, U.K.) 125, 4359-4367.
  6. [25]Erickson, S. L., O'Shea, K. S., Ghaboosi, N., Loverro, L., Frantz, G., Bauer, M., Lu, L. H. & Moore, M. W. (1997) Development (Cambridge, U.K.) 124, 4999-5011.
  7. [28]Stephenson, D. A., Mercola, M., Anderson, E., Wang, C. Y., Stiles, C. D., Bowen-Pope, D. F. & Chapman, V. M. (1991) Proc. Natl. Acad. Sci. USA 88, 6-10.
  8. [29]Morrison-Graham, K., Schatteman, G. C., Bork, T., Bowen-Pope, D. F. & Weston, J. A. (1992) Development (Cambridge, U.K.) 115, 133-142.
  9. [36]Gaussin, V., Van de Putte, T., Mishina, Y., Hanks, M. C., Zwijsen, A., Huylebroeck, D., Behringer, R. R. & Schneider, M. D. (2002) Proc. Natl. Acad. Sci. USA 99, 2878-2883.
  10. [38]Kumai, M., Nishii, K., Nakamura, K., Takeda, N., Suzuki, M. & Shibata, Y. (2000) Development (Cambridge, U.K.) 127, 3501-3512.
  11. [39]Kent, J., Wheatley, S. C., Andrews, J. E., Sinclair, A. H. & Koopman, P. (1996) Development (Cambridge, U.K.) 122, 2813-2822.

Cited by

Sorted by citations

Authors
Akiyama, H., Chaboissier, M.-C., Behringer, R. R., Rowitch, D. H., Schedl, A., Epstein, J. A., & de Crombrugghe, B.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Department of Molecular Genetics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; Institut National de la Santé et de la Recherche Médicale U470, Centre de Biochimie, Parc Valrose, 06108 Nice Cedex 2, France; Department of Pediatric Oncology, Dana–Farber Cancer Institute, Boston, MA 02115; and Cardiovascular Division, University of Pennsylvania, Philadelphia, PA 19104
Venue
Proceedings of the National Academy of Sciences
Published
2004-04-19
Volume
101
Issue
17
Pages
6502-6507
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2029022250
Cited by
265
References
41
Citations by year
2026: 5 · 2025: 12 · 2024: 3 · 2023: 11 · 2022: 19 · 2021: 11 · 2020: 11 · 2019: 10 · 2018: 13 · 2017: 13 · 2016: 2 · 2015: 14 · 2014: 9 · 2013: 17 · 2012: 14
FWCI
4.39
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (CA-16 672)
  • National Cancer Institute (CA-16672, P30CA016672)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
SOX9, endocardial cushion, epithelial-mesenchymal transition, NFATc1, HER3, cardiac jelly, endocardial endothelial cells, heart development
MeSH terms
Animals, Cell Division, Female, Heart Septum, Heart Valves, High Mobility Group Proteins, Mesoderm, Mice, Transgenic, Mutation, Pregnancy, Transcription Factors, Receptor, ErbB-3, Mice, SOX9 Transcription Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review